UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma

Internal Medicine, 2023/02/01, Vol.62(3), pp.475-479

2023

Volltextzugriff (PDF)

Arteritis after administration of granulocyte colony-stimulating factor: a case series

International journal of hematology, 2019-09, Vol.110 (3), p.370-374

2019

Volltextzugriff (PDF)

Aseptic Cavernosal Abscess: An Unrecognized Feature of Neutrophilic Dermatosis

Internal Medicine, 2022/03/15, Vol.61(6), pp.917-921

2022

Volltextzugriff (PDF)

Prognostic factors of Erdheim–Chester disease: a nationwide survey in Japan

Haematologica (Roma), 2018-11, Vol.103 (11), p.1815-1824

2018

Volltextzugriff (PDF)

Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry

Annals of hematology, 2021-12, Vol.100 (12), p.2989-2995

2021

Volltextzugriff (PDF)

Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis

International journal of hematology, 2019-10, Vol.110 (4), p.431-437

2019

Volltextzugriff (PDF)

Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based Treatment

Curēus (Palo Alto, CA), 2023-11

2023

Volltextzugriff (PDF)

Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy

Brain communications, 2020-01, Vol.2 (1), p.fcz048-fcz048

2020

Volltextzugriff (PDF)

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Blood, 2023-11, Vol.142 (Supplement 1), p.6625-6625

2023

Volltextzugriff (PDF)

Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting

Annals of hematology, 2024-09, Vol.103 (9), p.3811-3813

2024

Volltextzugriff (PDF)

Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.4-4

2020

Volltextzugriff (PDF)

The Clinical Features of Multiple Myeloma with AL Amyloidosis

Blood, 2020-11, Vol.136 (Supplement 1), p.10-10

2020

Volltextzugriff (PDF)

Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma

Internal Medicine, 2022, pp.9101-21

2022

Volltextzugriff (PDF)

Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma

International journal of hematology, 2024-07, Vol.120 (1), p.91-95

2024

Volltextzugriff (PDF)

Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment

Annals of hematology, 2023-06, Vol.102 (6), p.1477-1483

2023

Volltextzugriff (PDF)

Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies

Annals of hematology, 2023-12, Vol.102 (12), p.3489-3497

2023

Volltextzugriff (PDF)

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

Cancer Immunology, Immunotherapy, 2023-08, Vol.72 (8), p.2865-2871

2023

Volltextzugriff (PDF)

Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma

Acta haematologica, 2024-04, p.1-6

2024

Volltextzugriff (PDF)

Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation

Hematological oncology, 2024-01, Vol.42 (1), p.e3248-n/a

2024

Volltextzugriff (PDF)

Spinal Cord Infarction in a Patient with Immune Thrombocytopenic Purpura

Journal of stroke and cerebrovascular diseases, 2021-04, Vol.30 (4), p.105637, Article 105637

2021

Volltextzugriff (PDF)

A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee

International journal of hematology, 2023-10, Vol.118 (4), p.443-449

2023

Volltextzugriff (PDF)

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting

Hematological oncology, 2024-09, Vol.42 (5), p.e3306-n/a

2024

Volltextzugriff (PDF)

Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies

Hematological oncology, 2024-09, Vol.42 (5), p.e3302-n/a

2024

Volltextzugriff (PDF)

The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma

European journal of haematology, 2020-02, Vol.104 (2), p.110-115

2020

Volltextzugriff (PDF)

Retrospective Analysis of the Efficacy and Safety of Modified Bortezomib-Lenalidomide-Dexamethasonelite (modified RVD-lite) Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.1961-1961

2018

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(87)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma

Arteritis after administration of granulocyte colony-stimulating factor: a case series

Aseptic Cavernosal Abscess: An Unrecognized Feature of Neutrophilic Dermatosis

Prognostic factors of Erdheim–Chester disease: a nationwide survey in Japan

Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry

Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis

Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based Treatment

Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting

Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma

The Clinical Features of Multiple Myeloma with AL Amyloidosis

Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma

Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma

Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment

Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma

Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation

Spinal Cord Infarction in a Patient with Immune Thrombocytopenic Purpura

A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting

Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies

The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma

Retrospective Analysis of the Efficacy and Safety of Modified Bortezomib-Lenalidomide-Dexamethasonelite (modified RVD-lite) Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Suchergebnisse filtern